Company intelligence / Profile preview
Rocket Pharmaceuticals, Inc.
- Ownership
- Public · RCKT
- Employees
- ~150
- Development stage
- Phase 2
Overview
Advancing multiple gene therapy programs with positive Phase 1 results for RP-A501 for Danon Disease; initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA review ongoing for KRESLADI for LAD-I; Phase 1 trial of RP-A601 for PKP2-ACM ongoing with data expected in first half of 2025
- Therapeutic areas
- HematologyImmunologyRare DiseasesCardiovascular
- Modalities
- Gene therapy (ex vivo lentiviral vector and in vivo adeno-associated viral vector)
- Industry
- Biotech
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $396.4M
- Total revenue
- $0
- Enterprise value
- $137.4M
Beyond the preview
Go deeper on Rocket Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rocket Pharmaceuticals, Inc..